Shillitoe E J, Greenspan D, Greenspan J S, Silverman S
Cancer. 1986 Nov 15;58(10):2256-9. doi: 10.1002/1097-0142(19861115)58:10<2256::aid-cncr2820581016>3.0.co;2-g.
Levels of antibody to herpes simplex virus type 1 (HSV-1) were measured in 70 patients with untreated squamous cell carcinoma of the mouth. After treatment the actuarial survival was determined at quarterly intervals for 5 years and was found to be associated with the pretreatment level of antibody to the virus. Patients with levels of IgM antibody to HSV-1 which were above the median level had a 5-year survival of only 56% whereas those with levels below the median had a higher survival of 72%. Patients with no detectable IgM antibody to HSV-1 had a 5-year survival of 81%. The reverse was seen with IgG antibody to HSV-1. Patients with higher than the median level of IgG antibody had a 5-year survival of 73%, whereas those with IgG antibody below the median had a 5-year survival of 56%. No relationship was seen between survival and levels of IgA antibody to HSV-1, or between survival and antibody of any class to cytomegalovirus. The data are consistent with the reported association between oral cancer and HSV-1.
对70例未经治疗的口腔鳞状细胞癌患者检测了1型单纯疱疹病毒（HSV-1）抗体水平。治疗后，每季度测定一次5年的精算生存率，发现其与病毒抗体的预处理水平相关。HSV-1 IgM抗体水平高于中位数的患者5年生存率仅为56%，而低于中位数的患者生存率较高，为72%。未检测到HSV-1 IgM抗体的患者5年生存率为81%。HSV-1 IgG抗体情况则相反。IgG抗体水平高于中位数的患者5年生存率为73%，而低于中位数的患者5年生存率为56%。未发现生存与HSV-1 IgA抗体水平之间存在关联，也未发现生存与任何类别巨细胞病毒抗体之间存在关联。这些数据与报道的口腔癌与HSV-1之间的关联一致。
